Antibody‐drug conjugates(ADCs)are targeted biological agents composed of a cytotoxic drug linked to a monoclonal antibody through a linker.The monoclonal antibody targets tumor cells and transports small‐molecule cy...Antibody‐drug conjugates(ADCs)are targeted biological agents composed of a cytotoxic drug linked to a monoclonal antibody through a linker.The monoclonal antibody targets tumor cells and transports small‐molecule cytotoxic drugs for specific delivery and minimal off‐target side effects.It is necessary for clinicians to understand the molecular characteristics and mechanisms of ADCs.Patients'survival mainly depends on the appropriate dose and course of treatment and also on proper management of adverse reactions.This consensus provides a systematic review of commercially available ADCs and further discusses the clinical application and management of ADCs.展开更多
Cancer pharmacogenetics implies a complex combination of germline variants from the patient and somatic mutations in tumor cells.Somatic mutations meanwhile have become drugable targets or biomarkers,whereas germline ...Cancer pharmacogenetics implies a complex combination of germline variants from the patient and somatic mutations in tumor cells.Somatic mutations meanwhile have become drugable targets or biomarkers,whereas germline mutations potentially predict adverse drug effects or drug response.Here,we evaluate hereditary variants in biotransforming enzymes and drug transporters,such as thiopurine S-methyltransferase,UDP-glucuronosyltransferase(UGT1A1),dihydropyrimidine dehydrogenase(DPD),as well as ABC transporters(ABCB1,ABCG2 and ABCC subfamily)with respect to cytostatics and targeted therapies.Furthermore,gene expression regulation with regards to epigenetics and posttranscriptional modification are discussed.展开更多
文摘Antibody‐drug conjugates(ADCs)are targeted biological agents composed of a cytotoxic drug linked to a monoclonal antibody through a linker.The monoclonal antibody targets tumor cells and transports small‐molecule cytotoxic drugs for specific delivery and minimal off‐target side effects.It is necessary for clinicians to understand the molecular characteristics and mechanisms of ADCs.Patients'survival mainly depends on the appropriate dose and course of treatment and also on proper management of adverse reactions.This consensus provides a systematic review of commercially available ADCs and further discusses the clinical application and management of ADCs.
文摘Cancer pharmacogenetics implies a complex combination of germline variants from the patient and somatic mutations in tumor cells.Somatic mutations meanwhile have become drugable targets or biomarkers,whereas germline mutations potentially predict adverse drug effects or drug response.Here,we evaluate hereditary variants in biotransforming enzymes and drug transporters,such as thiopurine S-methyltransferase,UDP-glucuronosyltransferase(UGT1A1),dihydropyrimidine dehydrogenase(DPD),as well as ABC transporters(ABCB1,ABCG2 and ABCC subfamily)with respect to cytostatics and targeted therapies.Furthermore,gene expression regulation with regards to epigenetics and posttranscriptional modification are discussed.